tetano
Editor, Senior Moderator
NPJ Vaccines
. 2024 Nov 18;9(1):226.
doi: 10.1038/s41541-024-01022-8. Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity
Mathieu D'Souza[SUP] #[/SUP][SUP] 1 [/SUP], Alexa Keeshan[SUP] #[/SUP][SUP] 1 2 [/SUP], Christopher A Gravel[SUP] 2 3 4 5 [/SUP], Marc-André Langlois[SUP] 6 [/SUP], Curtis L Cooper[SUP] 7 8 9 [/SUP]
Affiliations
Obesity is a recognized factor influencing immune function and infectious disease outcomes. Characterization of the influence of obesity on SARS-CoV-2 humoral vaccine immunogenicity is required to properly tailor vaccine type (mRNA, viral-vector, protein subunit vaccines) and dosing schedule. Data from a prospective cohort study collected over 34 months was used to evaluate the slope of antibody production and decay and neutralizing capacity following SARS-CoV-2 vaccination in individuals with and without obesity at baseline. Most participants were female (65.4%), white (92.4%), and received mRNA vaccines. 210 were obese and 697 non-obese. Sex and infection-acquired immunity were identified as effect modifiers for the relationship between obesity and COVID-19 vaccine humoral immunogenicity. No consistent influence of obesity on peak titres, titre retention, antibody isotype (IgG, IgM, IgA), or neutralization was identified when controlling for other key variables. It may not be necessary to consider this variable when developing SARS-CoV-2 vaccine dosing strategies.
. 2024 Nov 18;9(1):226.
doi: 10.1038/s41541-024-01022-8. Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity
Mathieu D'Souza[SUP] #[/SUP][SUP] 1 [/SUP], Alexa Keeshan[SUP] #[/SUP][SUP] 1 2 [/SUP], Christopher A Gravel[SUP] 2 3 4 5 [/SUP], Marc-André Langlois[SUP] 6 [/SUP], Curtis L Cooper[SUP] 7 8 9 [/SUP]
Affiliations
- PMID: 39557875
- DOI: 10.1038/s41541-024-01022-8
Obesity is a recognized factor influencing immune function and infectious disease outcomes. Characterization of the influence of obesity on SARS-CoV-2 humoral vaccine immunogenicity is required to properly tailor vaccine type (mRNA, viral-vector, protein subunit vaccines) and dosing schedule. Data from a prospective cohort study collected over 34 months was used to evaluate the slope of antibody production and decay and neutralizing capacity following SARS-CoV-2 vaccination in individuals with and without obesity at baseline. Most participants were female (65.4%), white (92.4%), and received mRNA vaccines. 210 were obese and 697 non-obese. Sex and infection-acquired immunity were identified as effect modifiers for the relationship between obesity and COVID-19 vaccine humoral immunogenicity. No consistent influence of obesity on peak titres, titre retention, antibody isotype (IgG, IgM, IgA), or neutralization was identified when controlling for other key variables. It may not be necessary to consider this variable when developing SARS-CoV-2 vaccine dosing strategies.